North China Pharmaceutical Co Ltd (600812) — Financial Flexibility Index
North China Pharmaceutical Co Ltd (600812) has a Financial Flexibility Index of 0.02x as of September 2025. Free cash flow of CN¥314.62 Million (operating CF CN¥170.24 Million minus capex CN¥144.38 Million) represents 0% of total liabilities (CN¥14.86 Billion). Check 600812 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
North China Pharmaceutical Co Ltd Financial Flexibility Index (1998–2025)
Historical Financial Flexibility Index trend for North China Pharmaceutical Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see how efficiently does North China Pharmaceutical Co Ltd generate cash.
Annual Financial Flexibility Index for North China Pharmaceutical Co Ltd (1998–2025)
Year-by-year free cash flow to debt coverage for North China Pharmaceutical Co Ltd. Explore North China Pharmaceutical Co Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.12x | CN¥1.72 Billion | CN¥1.18 Billion | CN¥14.51 Billion | ▼ -13.0% |
| 2024 | 0.14x | CN¥2.01 Billion | CN¥1.23 Billion | CN¥14.80 Billion | ▲ +21.3% |
| 2023 | 0.11x | CN¥1.65 Billion | CN¥1.02 Billion | CN¥14.69 Billion | ▲ +8.2% |
| 2022 | 0.10x | CN¥1.55 Billion | CN¥1.00 Billion | CN¥14.99 Billion | ▲ +16.2% |
| 2021 | 0.09x | CN¥1.60 Billion | CN¥1.05 Billion | CN¥17.91 Billion | ▼ -14.4% |
| 2020 | 0.10x | CN¥1.76 Billion | CN¥752.15 Million | CN¥16.88 Billion | ▼ -2.4% |
| 2019 | 0.11x | CN¥1.38 Billion | CN¥732.97 Million | CN¥12.92 Billion | ▲ +3.4% |
| 2018 | 0.10x | CN¥1.28 Billion | CN¥774.33 Million | CN¥12.40 Billion | ▲ +78.4% |
| 2017 | 0.06x | CN¥686.94 Million | CN¥287.25 Million | CN¥11.87 Billion | ▲ +509.8% |
| 2016 | -0.01x | CN¥-157.93 Million | CN¥-446.53 Million | CN¥11.18 Billion | ▼ -130.9% |
| 2015 | 0.05x | CN¥490.31 Million | CN¥122.50 Million | CN¥10.73 Billion | ▲ +35.2% |
| 2014 | 0.03x | CN¥348.86 Million | CN¥90.56 Million | CN¥10.32 Billion | ▼ -17.3% |
| 2013 | 0.04x | CN¥425.92 Million | CN¥-135.03 Million | CN¥10.41 Billion | ▼ -61.7% |
| 2012 | 0.11x | CN¥1.00 Billion | CN¥-63.92 Million | CN¥9.36 Billion | ▼ -22.1% |
| 2011 | 0.14x | CN¥1.36 Billion | CN¥227.60 Million | CN¥9.95 Billion | ▲ +94.9% |
| 2010 | 0.07x | CN¥558.27 Million | CN¥-598.35 Million | CN¥7.94 Billion | ▼ -67.3% |
| 2009 | 0.21x | CN¥1.38 Billion | CN¥1.01 Billion | CN¥6.41 Billion | ▼ -5.8% |
| 2008 | 0.23x | CN¥1.22 Billion | CN¥1.09 Billion | CN¥5.37 Billion | ▲ +55.9% |
| 2007 | 0.15x | CN¥762.64 Million | CN¥664.37 Million | CN¥5.22 Billion | ▲ +26.5% |
| 2006 | 0.12x | CN¥648.84 Million | CN¥597.12 Million | CN¥5.61 Billion | ▲ +56.8% |
| 2005 | 0.07x | CN¥408.84 Million | CN¥224.17 Million | CN¥5.55 Billion | ▼ -34.1% |
| 2004 | 0.11x | CN¥658.89 Million | CN¥310.39 Million | CN¥5.89 Billion | ▼ -50.7% |
| 2003 | 0.23x | CN¥1.02 Billion | CN¥580.32 Million | CN¥4.51 Billion | ▲ +1.1% |
| 2002 | 0.22x | CN¥963.19 Million | CN¥738.50 Million | CN¥4.29 Billion | ▲ +86.1% |
| 2001 | 0.12x | CN¥559.07 Million | CN¥367.28 Million | CN¥4.63 Billion | ▲ +70.6% |
| 2000 | 0.07x | CN¥231.00 Million | CN¥133.49 Million | CN¥3.27 Billion | ▲ +171.7% |
| 1999 | -0.10x | CN¥-285.87 Million | CN¥-373.62 Million | CN¥2.90 Billion | ▲ +32.3% |
| 1998 | -0.15x | CN¥-292.55 Million | CN¥-326.74 Million | CN¥2.01 Billion | — |